MindWalk Holdings (HYFT) Long-Term Investments (2020 - 2023)
MindWalk Holdings (HYFT) posted quarterly Long-Term Investments of $20228.5 for Q3 2023, down 81.01% year-over-year from $106521.2 in Q3 2022, and down 76.2% quarter-over-quarter from $84990.7 in Q2 2023.
MindWalk Holdings (HYFT) Long-Term Investments (2020 - 2023) Analysis & Trends
MindWalk Holdings (HYFT) has reported Long-Term Investments for 4 consecutive years, with $20228.5 the latest figure, recorded in Q3 2023.
- In Q3 2023, Long-Term Investments fell 81.01% year-over-year to $20228.5; the TTM figure through Jul 2023 stood at $20228.5 (down 81.01% YoY), while the FY2023 annual figure was $84990.7, down 24.19% from the prior year.
- Long-Term Investments eased to $20228.5 in Q3 2023 per HYFT's latest filing, from $84990.7 in the prior quarter.
- Across five years, Long-Term Investments topped out at $112116.8 in Q2 2022 and bottomed at $20228.5 in Q3 2023.
- Historically, Long-Term Investments has averaged $82415.9 across 4 years, with a median of $86608.0 in 2020.
- Annual changes were most pronounced in 2022 — Long-Term Investments climbed 27.16% — and 2023, when it plunged 81.01%.
- MindWalk Holdings' Long-Term Investments stood at $87732.7 in 2020, then slipped by 3.89% to $84316.4 in 2021, then retreated by 20.53% to $67007.7 in 2022, then slumped by 69.81% to $20228.5 in 2023.
- Business Quant data shows HYFT's Long-Term Investments at $20228.5 in Q3 2023, $84990.7 in Q2 2023, and $71173.9 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2023 | 20,228.50 |
| Apr 30, 2023 | 84,990.66 |
| Jan 31, 2023 | 71,173.86 |
| Oct 31, 2022 | 67,007.69 |
| Jul 31, 2022 | 106,521.22 |
| Apr 30, 2022 | 112,116.83 |
| Jan 31, 2022 | 82,958.57 |
| Oct 31, 2021 | 84,316.40 |
| Jul 31, 2021 | 89,538.13 |
| Apr 30, 2021 | 88,167.03 |
| Jan 31, 2021 | 90,047.22 |
| Oct 31, 2020 | 87,732.70 |
| Apr 30, 2020 | 86,607.96 |